Boost knowledge guided cancer therapy
Clear insight in molecular modeling of every unique mutation, fast & precise
Protyon is focused on improving the efficacy of cancer treatment
During treatment, novel cancer mutations can emerge, leading to progression of the disease and a need for new treatment
This leaves clinicians the hard task to select a suitable therapy for each different tumour from a variety of approved drugs with little information on their likely effectiveness
Our solution boosts knowledge guided cancer therapy
We provide structural biology tools directly to the clinic allowing to first test the efficacy of the drugs with digital tools in tailor-made models of the patient’s cancer-driving proteins.
How Protyon
technology works
1. Input mutations of the cancer driven protein
We construct a digital 3D model of the cancer drivers from the patient’s molecular fingerprint.
2. Test available treatments
We then use the molecular models to test available therapies in a computer and analyze their efficacy to delay the cancer.
3. Output Report
We provide the clinician with a ranking of the drugs most likely to efficiently treat the individual patient’s disease.
Our approach enables better disease management and care, which ultimately improves the quality and length of life of the patients and reduces unnecessary side effects.
We have developed an approach to use 3D structural information on the cancer driving protein combined with computational analysis of its interaction with potential drugs. This new information for oncologists supports fast clinical decisions on a truly personalised level.
Establishing personalised treatment for each patient
Saves costs by eliminating ineffective treatments
Minimalise the side effects of unnecessary therapy
Knowledge based prediction of treatment outcome
Increases life expectancy of patients
Lowers the burden on health care
Improve prognosis for each patient
The team and members
Rositsa Jordanova
CEO
Hoang Nguyen
COO
Josef Melcr
CPTO
